Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies

Current Oncology Reports

Volumn 11, Issue 2, 2009, Pages 156-162

  Lee, Steve C ^b   López Albaitero, Andrés ^b   Ferris, Robert L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD16 ANTIGEN; CETUXIMAB; ERLOTINIB; GEFITINIB; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMC 11F8; PANITUMUMAB; PEMETREXED; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; ZALUTUMUMAB;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DENDRITIC CELL; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NATURAL KILLER CELL; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; COMPLEMENT PATHWAY, CLASSICAL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; RECEPTORS, IGG; T-LYMPHOCYTES;

EID: 60349114917     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0023-5     Document Type: Review

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. Lee SC, Shores CG, Weissler MC: Salvage surgery after failed primary concomitant chemoradiation. Curr Opin Otolaryngol Head Neck Surg 2008, 16:135-140.
3. Finn OJ: Cancer immunology. N Engl J Med 2008, 358:2704-2715.
4. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al.: Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004, 173:4699-4707.
5. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
6. Harari PM, Allen GWA Bonner JA: Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007, 25:4057-4065.
7. Lopez-Albaitero A, Ferris RL: Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007, 133:1277-1281.
8. Mailliard RB, Son YI, Redlinger R, et al.: Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function. J Immunol 2003, 171:2366-2373.
9. Moretta L, Ferlazzo G, Bottino C, et al.: Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006, 214:219-228.
10. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
11. Vermorken JB, Mesia R, Rivera F, et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
12. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
13. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982, 306:517-522.
14. Waldmann PA: Immunotherapy: past, present and future. Nat Med 2003, 9:269-277.
15. Weiner LM: Fully human therapeutic monoclonal antibodies. J Immunother 2006, 29:1-9.
16. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT: Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 1984, 81:6851-6855.
17. Boulianne GL, Hozumi N, Shulman MJ: Production of functional chimaeric mouse/human antibody. Nature 1984, 312:643-646.
18. Rubin Grandis J, Melhem MF, Gooding WE, et al.: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-832.
19. Mendelsohn J, Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33:369-385.
20. Li S, Schmitz KR, Jeffrey PD, et al.: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
21. Mandic R, Rodgarkia-Dara CJ, Zhu L, et al.: Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 2006, 580:4793-4800.
22. Yoshida T, Okamoto I, Okabe T, et al.: Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 2008, 122:1530-1538.
23. Wheeler DL, Huang S, Kruser TJ, et al.: Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
24. Forastiere AA, Burtness BA: Epidermal growth factor receptor inhibition in head and neck cancer-more insights, but more questions. J Clin Oncol 2007, 25:2152-2155.
25. Weiner GJ: Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007, 39:271-278.
26. Seiwert TY, Cohen EE: Targeting angiogenesis in head and neck cancer. Semin Oncol 2008, 35:274-285.
27. Fujita K, Sano D, Kimura M, et al.: Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2007, 18:47-51.
28. Roda JM, Joshi T, Butchar JP, et al.: The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007, 13:6419-6428.
29. Zhang W, Gordon M, Schultheis AM, et al.: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-3718.
30. Fricke I, Mirza N, Dupont J, et al.: Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007, 13:4840-4848.
31. Lewis GD, Figari I, Fendly B, et al.: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993, 37:255-263.
32. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947.
33. Weng WK, Czerwinski D, Timmerman J, et al.: Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004, 22:4717-4724.
34. Taylor C, Hershman D, Shah N, et al.: Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007, 13:5133-5143.
35. Varchetta S, Gibelli N, Oliviero B, et al.: Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007, 67:11991-11999.
36. Kimura H, Sakai K, Arao T, et al.: Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007, 98:1275-1280.
37. Dechant M, Weisner W, Berger S, et al.: Complementdependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008, 68:4998-5003.
38. Schmiedel J, Blaukat A, Li S, et al.: Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 2008, 13:365-373.
39. Dhodapkar MV, Dhodapkar KM, Li Z: Role of chaperones and FcgammaR in immunogenic death. Curr Opin Immunol 2008, 20:512-517.
40. Rafiq K, Bergtold A, Clynes R: Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002, 110:71-79.
41. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV: Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002, 195:125-133.
42. Harbers SO, Crocker A, Catalano G, et al.: Antibodyenhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 2007, 117:1361-1369.
43. Banerjee D, Matthews P, Matayeva E, et al.: Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgammaRs on human dendritic cells. J Immunother 2008, 31:113-120.
44. Cooper MA, Fehniger TA, Fuchs A, et al.: NK cell and DC interactions. Trends Immunol 2004, 25:47-52.
45. Lucas M, Schachterle W, Oberle K, et al.: Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517.
46. el-Shami K, Tirosh B, Bar-Haim E, et al.: MHC class Irestricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 1999, 29:3295-3301.
47. Tax WJ, Tamboer WP, Jacobs CW, et al.: Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation 1997, 63:106-112.
48. Paiva M, Marques H, Martins A, et al.: FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet 2008, 183:35-40.
49. Whiteside TL: Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005, 24:95-105.
50. Bergmann C, Strauss L, Wang Y, et al.: T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008, 14:3706-3715.
51. Lopez-Albaitero A, Nayak JV, Ogino T, et al.: Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006, 176:3402-3409.